[HTML][HTML] Anti-obesity medications and investigational agents: an obesity medicine association (OMA) clinical practice statement (CPS) 2022
HE Bays, A Fitch, S Christensen, K Burridge, J Tondt - Obesity Pillars, 2022 - Elsevier
Abstract Background This “Anti-Obesity Medications and Investigational Agents: An Obesity
Medicine Association Clinical Practice Statement 2022” is intended to provide clinicians an …
Medicine Association Clinical Practice Statement 2022” is intended to provide clinicians an …
Metabolic profiles associated with opioid use and opioid use disorder: a narrative review of the literature
JI Byanyima, X Li, SA Vesslee, HR Kranzler… - Current Addiction …, 2023 - Springer
Abstract Purpose of Review Opioid use disorder (OUD) is a chronic, relapsing condition that
is epidemic in the USA. OUD is associated with serious adverse consequences, including …
is epidemic in the USA. OUD is associated with serious adverse consequences, including …
Pharmacological therapies to address obesity in type 1 diabetes
The growing prevalence of obesity in T1D has created an unmet need for safe and effective
therapies to treat overweight and obesity in this population. Currently, antiobesity …
therapies to treat overweight and obesity in this population. Currently, antiobesity …
Chronic treatment with psilocybin decreases changes in body weight in a rodent model of obesity
J Huang, M Pham, WJ Panenka, WG Honer… - Frontiers in …, 2022 - frontiersin.org
Background There are currently relatively few effective pharmacological treatments for
obesity, and existing ones may be associated with limiting side-effects. In the search for …
obesity, and existing ones may be associated with limiting side-effects. In the search for …
[PDF][PDF] Setmelanotyd–od genów do terapii celowanej w niektórych, rzadkich formach otyłości
D Frączkowski - Farm Pol, 2021 - scholar.archive.org
Obesity is a serious public health concern. It significantly affects an individual's quality of life
and is associated with an increased risk of developing other conditions, including diabetes …
and is associated with an increased risk of developing other conditions, including diabetes …
Pediatric obesity psychopharmacology: Quo vadis?
MD Flora Bacopoulou… - Journal of Alternative …, 2022 - search.proquest.com
Obesity is a major risk factor for child, adolescent and adult health. Though diet and exercise
are the cornerstone of obesity prevention and treatment, many pediatric persons do not …
are the cornerstone of obesity prevention and treatment, many pediatric persons do not …
Hypothalamic circuits mediating consumption and anxiety
R Cassidy - 2020 - digitalcommons.library.tmc.edu
Abstract From 1960-2016, US obesity prevalence increased 13-40% and diabetes
increased from 3-15%. There is an epidemic of metabesity, the aggregate metabolic …
increased from 3-15%. There is an epidemic of metabesity, the aggregate metabolic …